The Drug Enforcement Administration this week proposed reducing aggregate production quotas for five opioid controlled substances in 2020. The proposal would reduce the amounts of fentanyl by 31%, hydrocodone by 19%, hydromorphone by 25%, oxycodone by 9% and oxymorphone by 55%. The five opioid substances were subject to special scrutiny following the enactment last year of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, which requires DEA to estimate the amount of diversion of the covered substance that occurs in the United States and make appropriate quota reductions. DEA will accept comments on the 2020 proposed aggregate production quotas, which address more than 250 Schedule I and II controlled substances, through Oct. 15.

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
The AHA, American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical…
Headline
Reps. Scott Peters, D-Calif., Eliot Engel, D-N.Y., Brett Guthrie, R-KY, Anna Eshoo, D-Calif., Richard Hudson, R-N.C., Michael McCaul, R-Texas, Kurt Schrader, D…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…
Headline
Public and private entities can apply for $1 million grants for a three-year period to enhance or expand opioid and other substance use disorder services in…